Here's Why Addex Therapeutics (VTX:ADXN) Must Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Swiss (SMI) Biotech Industry Analysis
UpdatedMay 22, 2022
DataAggregated Company Financials
Companies7
- 7D3.2%
- 3M-46.1%
- 1Y-64.3%
- YTD-38.5%
The Biotech industry is up 3.2% in the last week, with Idorsia up 3.6%. In the same time, Addex Therapeutics was down 11%. However, the industry is down 64% over the past year. Looking forward, earnings are forecast to decline by 38% per year.
Industry Valuation and Performance
Has the Swiss Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Sun, 22 May 2022 | CHF719.6m | CHF471.4m | CHF25.1m | 2.1x |
| Tue, 19 Apr 2022 | CHF1.1b | CHF291.9m | -CHF142,532,527.00 | 1.9x |
| Thu, 17 Mar 2022 | CHF1.2b | CHF285.6m | -CHF140,575,871.00 | 1.9x |
| Sat, 12 Feb 2022 | CHF1.4b | CHF282.9m | -CHF138,870,474.00 | 1.8x |
| Mon, 10 Jan 2022 | CHF4.7b | CHF317.7m | -CHF658,979,620.00 | 1.5x |
| Wed, 08 Dec 2021 | CHF3.8b | CHF319.1m | -CHF658,785,712.00 | 1.5x |
| Fri, 05 Nov 2021 | CHF4.3b | CHF315.2m | -CHF658,961,084.00 | 2.3x |
| Sun, 03 Oct 2021 | CHF5.1b | CHF288.3m | -CHF590,726,662.00 | 4.9x |
| Tue, 31 Aug 2021 | CHF5.2b | CHF306.0m | -CHF612,309,374.80 | 1.1x |
| Wed, 07 Jul 2021 | CHF5.8b | CHF306.0m | -CHF612,309,374.80 | 1.1x |
| Sat, 10 Apr 2021 | CHF6.2b | CHF352.3m | -CHF535,605,963.80 | 3.8x |
| Fri, 01 Jan 2021 | CHF6.1b | CHF407.2m | -CHF561,055,198.50 | 7.1x |
| Mon, 05 Oct 2020 | CHF5.7b | CHF399.6m | -CHF565,530,866.50 | 1x |
| Thu, 09 Jul 2020 | CHF4.9b | CHF393.6m | -CHF565,357,804.50 | 30x |
| Wed, 01 Apr 2020 | CHF788.5m | CHF327.2m | -CHF114,875,385.50 | 6.6x |
| Sat, 04 Jan 2020 | CHF4.6b | CHF460.8m | -CHF670,400,644.00 | n/a |
| Tue, 08 Oct 2019 | CHF3.9b | CHF473.1m | -CHF646,955,470.00 | n/a |
| Mon, 01 Jul 2019 | CHF3.6b | CHF449.1m | -CHF654,647,900.00 | n/a |
Median PE Ratio
n/a
Current Industry PEThere are only 2 profitable companies in this industry, so there is insufficient data to make an industry-wide assessment of PE.
Past Earnings Growth
- Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable.
- Revenues have remained mostly flat. This means that the industry has become more efficient since profits are increasing while sales have been flat.
Industry Trends
Which industries have driven the changes within the Swiss Healthcare industry?
| CH Market | -2.84% | |
| Healthcare | 0.093% | |
| Biotech | 3.15% | |
| Biotech | 3.15% | |
Industry PE
- Investors are most optimistic about the Biotech industry even though it's trading below its 3-year average PE ratio of 24.2x.
- Analysts are expecting annual earnings decline of 38%, which is lower than the prior year's growth of 52% per year.
- This could indicate that the market believes that analysts are underestimating future growth or they expect the Biotech industry's earnings to deteriorate the least compared to other industries.
Forecasted Growth
- Despite it being negative, analysts are least pessimistic on the Biotech industry since they expect its earnings to decline by only 38% per year over the next 5 years, which isn't as bad as the other industries.
- This is a reversal from its past annual earnings growth rate of 52% per year.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| IDIA Idorsia | CHF15.17 | 3.6% +CHF93.9m | -35.2% | PS79.8x | |
| BSLN Basilea Pharmaceutica | CHF32.60 | 5.0% +CHF18.4m | -26.3% | PS2.6x | |
| RLF Relief Therapeutics Holding | CHF0.056 | 6.4% +CHF14.0m | -73.2% | PS70.3x | |
| MOLN Molecular Partners | CHF7.28 | 5.5% +CHF12.4m | -69.2% | PS2.2x | |
| SANN Santhera Pharmaceuticals Holding | CHF1.33 | 4.7% +CHF2.2m | -40.6% | PS4.1x |
